As the first month of 2022 draws to a close, the internet has been filled with trend forecasts for the coming year. Bloggers, Twitter influencers and well-known entrepreneurs have been and continue to be incredibly excited about the new opportunities offered by the explosion of Web3 innovation. However, what you may have missed on the rolling pages of celebrity-backed NFT predictions or meta-speculations is the launch of a new company called Altos Labs, backed by former Amazon CEO Jeffrey Bezos.
The language that followed the launch was quite typical of a number of random journalists who talked about the sector for a long time, and words like vague and secretive. I have written in previous articles that there are many misconceptions about the sector for longevity, and this new round of headlines seems to confirm that this is still true.
Related topics: The Future of Longevity is in Cryptovision
I think there is more to the longevity sector than secret deals involving the richest billionaires on the planet. The place is full of interested investors, groundbreaking discoveries and development opportunities. The message is clear – a long life is here to stay. And for the cryptocurrency industry, or for a world filled with trend-setting and tech-savvy people, it’s time to start accelerating in this incredible space.
Transaction continuity
Although the Altos Labs agreement was surrounded by little-known rhetoric in the media, it indicated a high level of interest in the diverse lifespan sector. The deal, which was awarded $ 3 billion on the first day, is considered the largest biotechnology deal to date and has attracted relevant talent. The senior management consists of world-renowned researchers, managers and clinicians who are committed to finding new frontiers in the science of anti-aging.
Altos ads remind us of Calico Labs, another long-lived company that was announced in 2013 by Google co-founder Larry Page. Although the Google subsidiary has been asked about the performance, it published its first publication on cell programming in May 2021. Not only have IT executives been in the investment headlines: Agreements in the last two months alone include areas such as stem cell therapy, liver regeneration, anti-aging , reproductive life and more.
It is clear that the best innovators on the planet want to live longer. It is in our power to ensure that sustainability technology becomes available to all when it becomes available to the public.
Related topics: Crypto-leaders are obsessed with life extension. Therefore
discoveries of longevity
Insilico Medicine, a Hong Kong-based drug development company, announced a major breakthrough in late 2021. The first drug detected by artificial intelligence has been tested on humans. The drug will be used to treat idiopathic pulmonary fibrosis, a chronic lung disease, and early studies have shown promising early results. It is the first substance discovered by artificial intelligence that has reached this stage, and an exciting indicator of new inventions to come. Artificial intelligence is a key area for long-term research, with countless uses for drug discovery and beyond.
Other exciting new areas include cell regeneration, plant-based supplements and advances in portable technology that help track aging-related diseases. Charities such as VitaDAO and the Longevity Science Foundation work tirelessly to fund research on these early ideas and help them gain public acceptance.
Related topics: The next generation of computer-driven healthcare is here
development of the continuity sector
On Deck, a company that offers accelerator programs for the best professionals from various sectors, launched the first Longevity Biotech Fellowship in June 2021. The first group was attended by leading companies in longevity and biotechnology, including Turn.bio, Juvena Therapeutics, Retro Sciences and more. Researchers from universities such as Yale University, the University of Washington and ETH Zurich have also contributed to the coordinated community. On Deck is currently accepting applications for a second set starting later this month. Society claims to push the boundaries of traditional health and expand the biotechnology ecosystem one member at a time.
